Krystal Massey, MD
Dermatology · Cheyenne, WYNPI 1043630619
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,263 of the $8,823 with a category attached, or 71.0%. Lilly USA, LLC accounts for 73.8% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $6,757, more than ten times the $146 reported in 2020.
Across 151 payments — averaging $58.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$7K
- AbbVie$1K
- Novartis$197
- Sanofi$170
- Amgen$167
- Regeneron Healthcare Solutions, Inc.$118
- plus $483 from 12 others
Across 29 payments — averaging $10,859 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$279K
- Sanofi$20K
- Sun Pharmaceutical Industries Inc.$16K
What the payments were for
- Consulting fees$6,26371%
- Travel & lodging$1592%
- Food & beverage$2,30326%
- Education$991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 11 | $6,514 |
| AbbVie(2 entities) | 83 | $1,174 |
| Novartis | 10 | $197 |
| Sanofi | 9 | $170 |
| Amgen | 10 | $167 |
| Regeneron Healthcare Solutions, Inc. | 6 | $118 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Galderma Laboratories, L.p. | 4 | $92 |
| Johnson & Johnson | 5 | $82 |
| Sun Pharmaceutical Industries Inc. | 3 | $47 |
| LEO Pharma Inc. | 2 | $41 |
| Organogenesis Inc. | 1 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| VYNE Pharmaceuticals Inc. | 1 | $19 |
| Biofrontera Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Biowound Solutions, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few dermatology providers in Wyomingto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 20 | $87,858 |
| Acitretin | 29 | $7,597 |
| Clobetasol Propionate | 76 | $4,184 |
| Fluorouracil | 62 | $4,001 |
| Tacrolimus | 13 | $1,913 |
| Ketoconazole | 50 | $781 |
| Clindamycin Phosphate | 12 | $749 |
| Hydroxychloroquine Sulfate | 19 | $558 |
| ValacyclovirValacyclovir Hcl | 24 | $471 |
| Triamcinolone Acetonide | 45 | $290 |
| Fluconazole | 17 | $275 |
| Mupirocin | 15 | $153 |
| Cephalexin | 12 | $124 |
| Terbinafine Hcl | 11 | $119 |
| Hydrocortisone | 16 | $92 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Cheyenne
- Gregory SeitzCheyenne$2K
- Sandra SurbruggCheyenne$2K
- Julie NevilleCheyenne$1K
- Mary ColeCheyenne$957
- Samuel EckerLaramie$3K
- Tyler QuestCasper$2K
- Matthew GreenCasper$2K
- Scott BennionCasper$2K
- Melissa RhoadesGillette$2K
- Jonathan BakerJackson$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.